ADARx Teams with Westwood & Wilshire to Place Chief Financial Officer

Silicon Valley, Calif., September 19, 2022— ADARx, a platform technology company with the power to edit, degrade and inhibit RNA, announced this week the appointment of Chris Prentiss as Chief Financial Officer. ADARx is currently focused on diseases in three therapeutic areas: genetic, cardiometabolic diseases, and central nervous system diseases and has 11 active programs in development with three assets at IND-enabling stage. The company has over $100 million raised from OrbiMed, SR One, Lilly Asia Ventures and Sirona.

Chris Prentiss brings over 23 years of experience, starting in industry at Mannkind and Intermune with a series of promotions, extensive experience financing clinical development, partnering, M&A and IR activities. He joins ADARx from Adamas, where he was the CFO and guided the company through a successful acquisition. Chris received his MBA from Indiana University’s Kelley School of Business.

The search was led successfully by Tamir Halaban and Andrea Tegstam for Westwood & Wilshire.

About Westwood & Wilshire

Westwood & Wilshire is a retained executive-search firm delivering premier talent in life sciences, healthcare and advanced technology to the world’s most innovative companies. Our specialty is bringing top-flight, senior leadership candidates to growing venture-backed companies looking for the best people to fill their C-Suite hires. Clients around the globe work with Westwood & Wilshire recruiters, who are based in Los Angeles, Silicon Valley, Scottsdale and the New York metro area. Contact information can be found at https://westwoodwilshire.com/contact-us.